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ABSTRACT: In two studies conducted from October 1999 to March 2000 and December 2000
to April 2001, adult black bears (Ursus americanus) were orally inoculated with 1.4–3.131010
colony-forming units (CFU) of Brucella abortus strain RB51 (SRB51, n512) or 2 ml of 0.15 M
NaCl solution (saline, n511). We did not detect a difference (P.0.05) in antibody titers to SRB51
in serum obtained before vaccination, at 8 wk after vaccination, or at necropsy at 21 or 23 wk
after vaccination between SRB51-vaccinated and nonvaccinated bears. The SRB51 vaccine strain
was recovered from tissues obtained at necropsy from one of six SRB51-vaccinated bears in study
1, but none of the six SRB51-vaccinated bears in study 2. Vaccination of black bears with SRB51
did not appear to influence (P.0.05) reproductive performance.
Key words: Biosafety, Brucella, RB51, serology, Ursus americanus, vaccine.

INTRODUCTION

In 1996, a new official calfhood vaccine
for cattle, Brucella abortus strain RB51
(SRB51), was conditionally approved by
the Animal and Plant Health Inspection
Service branch of the US Department of
Agriculture. The SRB51 strain, a laboratory-derived, lipopolysaccharide O–side
chain–deficient mutant (Schurig et al.,
1991) of B. abortus strain 2308, induces
protection in cattle and bison (Bison bison)
against challenge exposure with virulent B.
abortus strains (Cheville et al., 1993; Cheville et al., 1996; Olsen et al., 2003). Because SRB51 is being considered as a vaccine for bison in the Greater Yellowstone
Area (GYA, USA), studies to evaluate the
safety of this vaccine in representative
nontarget species needed to be conducted.
In the studies reported here, antibody responses, tissue localization and clearance,
and reproductive performance were assessed in black bears (Ursus americanus)
after oral exposure to SRB51.
MATERIALS AND METHODS

Two studies were conducted from October
1999 to March 2000 and December 2000 to
April 2001 at a private facility in South Dakota,
429

USA (428529N, 938639W). Each study used different bears with no animals used in both studies. In October (study 1) or December (study
2), adult black bears were sedated with 500 to
1,000 mg of tiletamine hydrochloride and zolazepam hydrochloride (Telazolt; Fort Dodge
Animal Health, Fort Dodge, Iowa, USA) administered intramuscularly by pneumatic dart
(Pneudartt, Williamsburg, Pennsylvania, USA).
After attainment of lateral recumbency, ear tags
were placed for identification, and blood was
obtained via jugular venipuncture for serologic
analysis. Bears were then orally inoculated by
placing the inoculum into the pharyngeal region and holding the head vertically until the
bear was observed to swallow. In study 1, bears
received either 2 ml of 0.15 M NaCl (saline;
n56) or 2 ml of saline containing B. abortus
strain RB51 (SRB51; n56) orally. In study 2,
only bears in the SRB51 treatment group
(n56) were anesthetized and inoculated orally.
However, control bears (n55) were identified
at the time of vaccination for comparison with
reproduction in SRB51-inoculated bears. Following oral inoculation, bears were grouped by
treatment, with SRB51-vaccinated bears
housed separately from nonvaccinated bears.
The SRB51 inoculum in both studies was
prepared by dilution of lyophilized SRB51 vaccine (Colorado Serum Company, Denver, Colorado, USA) to approximately 131010 colonyforming units (CFU) on the basis of viability
counts of other vials with the same lot number.
Briefly, reconstituted vaccine was serially diluted in saline and plated on tryptose agar plates
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containing 5% bovine serum, and standard
plate counts were conducted to determine viability. Standard plate counts of the inoculum
determined the SRB51 dosage administered.
At 8 wk after oral inoculation in study 1,
bears in both SRB51 and control treatments
were anesthetized with Telazol, as previously
described, and blood was obtained via jugular
venipuncture for serologic analysis.
Necropsy

At 23 wk after oral inoculation in study 1,
SRB51-inoculated bears and their cubs and
control bears were anesthetized in their dens
with Telazol via pneumatic dart or intramuscular injection. In a similar manner, SRB51-inoculated bears and their cubs in study 2 were
anesthetized in their dens at 21 wk after inoculation. After sedation, blood was obtained for
serology via jugular venipuncture. All SRB51inoculated bears and their cubs in both studies
were then euthanized with intravenous injections of sodium pentobarbitol (Sleepaway, Ft.
Dodge Labs, Ft. Dodge, Iowa) and necropsied.
Control bears were only sedated in study 1, and
all were allowed to recover from anesthesia.
Maternal tissues collected at necropsy from
SRB51 vaccinates for both bacteriologic and
histologic evaluation included: mammary gland,
liver, lung, spleen, kidney, and uterus. Maternal
samples obtained for bacteriologic examination
only included vaginal, conjunctival, nasal, and
rectal swabs; blood; tonsil; and hepatic, parotid,
popliteal, prescapular, medial retropharyngeal,
mediastinal, internal iliac, mandibular, mesenteric, and supramammary lymph nodes. Bacteriologic samples from cubs included blood,
spleen, lung, liver, kidney, mesenteric lymph
node, and cerebrospinal fluid. Histologic techniques also were used to examine cardiac samples from both sows and cubs and fetal liver,
spleen, and kidney samples. All tissues collected for histologic evaluation were fixed in neutral buffered 10% formalin embedded in paraffin, sectioned at 5 mm, and stained with hematoxylin and eosin. Special stains (Congo red,
silver, acid-fast, or Prussian blue; Sheehan and
Hrapchak, 1980) were performed on sections
in which examination of hematoxylin and eosin
sections suggested that additional histologic
techniques were warranted.
Bacteriologic evaluation

Tissue samples were triturated in saline and
placed on tryptose agar plates containing 5%
bovine serum and a selective medium for
SRB51 (RBM) that contains antibiotics, including rifampicin (Hornsby et al., 2000). The antibiotics in RBM media minimized growth of

contaminants without inhibiting growth of
SRB51, thereby enhancing the ability to detect
small numbers of SRB51 within samples.
Following incubation of plates at 37 C and
5% CO2 for 7 days, SRB51 was identified by
colony morphology, growth characteristics (Alton et al., 1988), and resistance to rifampicin
(Schurig et al., 1991). Isolates were confirmed
as SRB51 in a polymerase chain reaction (PCR)
procedure with the use of primers specific for
SRB51 (Vemulapalli et al., 1999). Briefly, the
reaction mixture consisted of heat-killed cells,
0.2 mM nucleotide mix (Boehringer Mannheim, Mannheim, Germany), 13 PCR Buffer
II (Perkin Elmer, Branchburg, New Jersey,
USA), 2.5 U/ml DNA polymerase (Amplitaq
Gold, Perkin Elmer), and 1.5 mM MgCl combined with 0.2 mM per reaction of specific
primers (upstream primer GCAACGGTGTTCTTCCACTC and downstream primer GTATCAGGCTACGCAGAAGG) for B. abortus
omp2A as selected from analysis of its sequence (Ficht et al., 1989). The samples, including positive and negative controls, were cycled (30 sec at 95 C, 30 sec at 44 C, 1 min at
72 C) 30 times in a thermocycler (MJ Research
Inc., Watertown, Massachusetts, USA). Products were analyzed by electrophoresis on a
1.5% agarose gel after staining with ethidium
bromide.
Serologic evaluation

Blood samples were allowed to clot, and serum was separated by centrifugation. Serum
was divided into 1-ml aliquots, frozen, and
stored at 270 C. Serologic titers of animals to
SRB51 were determined by dot-blot assay (Olsen et al., 1997) in which g-irradiated SRB51
is used as antigen, and peroxidase-labeled protein A (1:100 dilution; Kirkegaard and Perry
Laboratories Inc., Gaithersburg, Maryland,
USA), rabbit anti-canine IgG heavy- and lightchain antibodies (1:5,000; Jackson Immunoresearch Laboratories, West Grove, Pennsylvania), or rabbit anti-goat IgG heavy- and lightchain antibodies (1:10,000 dilution; Jackson
Immunoresearch Laboratories) were used as
secondary antibodies.
Statistics

Because of logarithmic conversions, titers
with a value of 0 were analyzed with a value of
1. Serologic responses of bears in both studies
were compared over all times by an analysis of
variance procedure with titers to each secondary antibody evaluated separately (SAS Institute Inc., Cary, North Carolina, USA). Means
for individual treatments were separated by a
least significant difference procedure (P,0.05).

OLSEN ET AL.—SAFETY OF RB51 IN BLACK BEARS

431

FIGURE 1. Serologic responses of nonvaccinated (control) bears or bears orally inoculated with 1.4–
3.131010 colony forming units of SRB51 to g-irradiated SRB51 in a dot-blot assay in which peroxidaseconjugated protein A, rabbit anti-canine IgG, or rabbit anti-goat IgG were used as secondary antibodies.
Antibody responses were determined before vaccination (time 0; n512 for SRB51 and n56 for control treatments), 8 wk after vaccination (n56 for SRB51 and control treatments), and at necropsy 21 or 23 wk after
vaccination (n512 for SRB51 and n56 for control treatments). Responses are presented as mean titer6SEM.

A 95% confidence interval was predicted from
the bacteriologic data by a Clopper-Pearson
procedure (SAS Institute Inc.).
RESULTS

The concentration of viable SRB51 bacteria within the inocula for studies 1 and
2 were determined by standard plate
counts to be 1.431010 and 3.131010 CFU,
respectively.
At necropsy in the first study, twin cubs
were found with one SRB51-inoculated
bear and one nonvaccinated bear. No other bears in SRB51 or control treatments
were pregnant or had cubs present at the
time of evaluation. In study 2, three of the
five paired controls had cubs (two triplets
and one set of twins) at the time of necropsy, whereas three of six SRB51-inoculated bears had cubs (three sets of twins).
At necropsy in study 1, 23 wk after vaccination, SRB51 was recovered from the
internal iliac, retropharyngeal, and mesenteric lymph nodes from one of six

SRB51-inoculated bears. This bear had no
cubs and was not pregnant at the time of
evaluation. The SRB51 vaccine strain was
not recovered from fetal tissues obtained
at necropsy from the two cubs of the
SRB51 vaccinate. In study 2, SRB51 was
not recovered from any tissue obtained at
necropsy from any of the six SRB51-inoculated bears or their cubs.
Regardless of secondary antibody, titers
of bears orally inoculated with SRB51 did
not differ (P.0.05) from dot-blot titers of
nonvaccinates at any sampling time (Fig.
1). In both studies, one of six SRB51-inoculated bears had titers at necropsy that
were four dilutions greater than the titer
of paired serum obtained before vaccination. In both of these bears, the highest
titers were noted when the anti-canine antibody was used as the secondary antibody.
When compared with the serum obtained
before inoculation, the bear that was culture positive for SRB51 at necropsy in
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study 1 did not demonstrate a significant
increase in titer to SRB51 at 8 wk after
inoculation or at necropsy with any of the
secondary antibodies used in this study.
With the exception of small, subacute,
multifocal tonsillar abscesses in one
SRB51-inoculated sow in study 1, no gross
lesions were noted at necropsy.
Histologic evaluation of lung sections
from eight SRB51-vaccinated adult bears
(five in study 1 and three in study 2) revealed multifocal, perivascular, and, to a
lesser extent, peribronchiolar accumulations of moderate numbers of histiocytes.
The cytoplasm of these histiocytes were
expanded by an amorphous basophilic material that also contained numerous birefringent crystals. In some adult bears, multifocal accumulations of low numbers of
lymphocytes were found in interstitial areas of the kidney or were randomly distributed in hepatic parenchyma.
Special stains of histologic sections of
lung indicated that lesions were compatible with pneumoconiosis. The etiology of
the particulate material in pulmonary sections was not conclusively determined but
most likely was inhaled environmental debris. With these exceptions, no significant
histologic lesions were noted in examination of remaining maternal tissues and all
fetal tissues.
DISCUSSION

The results of these studies suggest that
oral exposure to 1010 CFU of SRB51 is not
associated with adverse clinical, histologic,
or reproductive effects in bears. Although
bears in both treatments had poor conception rates in the first study, reproduction
performance of bears in both treatments
in each study were similar.
Our data also suggest that in a small
percentage of bears (one of 12, 8%; 95%
confidence interval, 0.2–38.5%), SRB51
can persist for up to 23 wk after oral inoculation. Failure to recover SRB51 from
mucosal swabs, mammary gland, supramammary lymph nodes, or uterine and fetal tissues in any SRB51-vaccinated bear in

our studies suggests that if bears are orally
exposed to SRB51, it is unlikely that they
will transmit the strain laterally or vertically. When evaluated with the bacteriologic data, the poor serologic responses
noted in our studies might indicate SRB51
is not well adapted to colonize or replicate
in tissues of black bears and therefore does
not effectively induce immunologic responses or cause clinical effects. Alternatively, SRB51 might not efficiently attach
and invade mucosal surfaces of black bears
after oral exposure.
Data from others have suggested that
bears in areas with endemic brucellosis
might undergo at least transient infection
with field strains of B. abortus. Grizzly
(Ursus arctos horribilis) and black bears
sampled in Montana (USA) near Yellowstone National Park demonstrated positive
responses on a panel of brucellosis serologic tests, whereas samples from bears in
northern Montana, in an area without brucellosis, were negative on the same panel
of tests (K. Aune, pers. comm.). Although
there are no data at this time to determine
whether exposure to B. abortus has any effects on survival or reproduction of bears
in the GYA, our data and studies in other
species (Januszewski et al., 2001; Kreeger
et al., 2002) suggest that SRB51 is safe in
black bears and is unlikely to be more
pathogenic in bears than B. abortus field
strains that are currently present in the
GYA environment.
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